First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

Objectives Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting.Design Retrospective, observational multicentre study.Setting We retrosp...

Full description

Saved in:
Bibliographic Details
Main Authors: Katja Menzler, Peter Michael Mross, Felix Rosenow, Susanne Schubert-Bast, Laurent Maximilian Willems, Felix Zahnert, Ilka Immisch, Sven Fuest, Felix von Podewils, Rhina Kunz, Martin Hirsch, Tamara Mueller, Justus Marquetand, Yaroslav Winter, Lisa Langenbruch, Michal Cicanic, Stefan Beyenburg, Adam Strzelczyk, Susanne Knake
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/11/e030746.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/9/11/e030746.full

Similar Items